Longer-term data show that donanemab’s cognitive benefits continue to grow over time, and earlier initiation reduces the risk for progression, with no new safety signals.

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

Eli Lilly (LLY) stock in focus as the company's neuroscience chief Anne White retires, and the firm begins an executive ...

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

Treatment with IV donanemab in early-stage Alzheimer’s disease demonstrated sustained clinical benefits for up to 3 years, with early initiation responsible for better outcomes, data from a long-term ...

Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company ...

Eli Lilly’s Alzheimer’s disease (AD) drug Kisunla ( donanemab) has demonstrated a growing benefit over three years in ...

Chinese authorities did not renew a conditional approval of Green Valley Pharmaceuticals’ controversial Alzheimer’s disease ...

Rates of diagnosis and treatment are low, so there is need for diagnostic tests and biomarkers for classification and ...

"Driven by urgent unmet needs and scientific advances, the Alzheimer's Disease DMT market is poised for rapid growth as pharmaceutical companies shift their focus to multi-target therapies that ...